Neurocognitive Effects of Chemotherapy and Endocrine Therapies in the Treatment of Breast Cancer: Recent Perspectives

REFERENCES

• Jemal A, Siegel R, Ward, E, Hao Y, Xu J, Thun M. Cancer Statistics, 2009. CA Cancer J Clin 2009;59(4):225–249.
   PubMed Web of Science ®Google Scholar
• United States. Cancer Care Issues in the United States: Quality of Care, Quality of Life. Bethesda, Md: National Cancer Program, National Cancer Institute, 1998.
   Google Scholar
• Ferrell B, Hassey DK. Quality of life among long-term cancer survivors. Oncology 1997;11:565–576.
   PubMedGoogle Scholar
• Morse R, Rodgers J, Verrill M, Kendell K. Neuropsychological functioning following systemic treatment in women treated for breast cancer: a review. Eur J Cancer 2003;39:2288–2297.
   PubMed Web of Science ®Google Scholar
• Cancer Facts and Figures 2010. Atlanta, GA: American Cancer Society.
   Google Scholar
• Wieneke MH, Dienst ER. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-Oncology 1995;4:61–66.
   Web of Science ®Google Scholar
• van Dam FS, Schagen SB, Muller MJ, Boogerd W, Wall E, Droogleever Fortuyn ME, Rodenhuis S. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high dose versus standard-dose chemotherapy. J Natl Cancer I 1998;90:210–218.
   PubMed Web of Science ®Google Scholar
• Wefel JS, Lenzi R, Theiault R, Buzdar AU, Cruickshank S, Meyers CA. Chemobrain in breast carcinoma? A prologue. Cancer 2004;101:466–475.
   PubMed Web of Science ®Google Scholar
• Donovan KA, Small BJ, Andrykowski MA, Schmitt FA, Munster P, Jacobsen PB. Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early-stage breast carcinoma. Cancer 2005;104:2499–2507.
   PubMed Web of Science ®Google Scholar
• Jenkins V, Shilling V, Deutsch G, Bloomfield D, Morris R, Allan S, Bishop H, Hodson N, Mitra S, Sadler G, Shah E, Stein R, Whitehead S, Winstanley J. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Brit J Cancer 2006;94:828–834.
   PubMed Web of Science ®Google Scholar
• Ahles TA, Saykin AJ. Breast cancer chemotherapy-related cognitive dysfunction. Clin Breast Cancer 2002;3(Suppl 3):S84–S90.
   PubMedGoogle Scholar
• Ferguson RJ, Ahles TA. Low neuropsychological performance among adult cancer survivors treated with chemotherapy. Curr Neurol Neurosci Rep 2003;3:215–222.
   PubMedGoogle Scholar
• Ahles T, Saykin A, Furstenberg CT, Cole B, Mott LA, Skalla K, Whedon MB, Bivens S, Mitchell T, Greenburg ER, Silberfarb PM. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 2002;20:485–493.
   PubMed Web of Science ®Google Scholar
• Tannock IF, Ahles TA, Ganz PA, van Dam FS. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol 2004;22:2233–2239.
   PubMed Web of Science ®Google Scholar
• Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat. Rev. Cancer 2007;7:192–201.
   PubMed Web of Science ®Google Scholar
• Weiss B. Chemobrain: A translational challenge for neurotoxicology. Neuro Toxicology 2008;29:891–898.
   Google Scholar
• Brezden C, Phillips KA, Abdolell M, Bunston T, Tannock IF. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2000;18:2695–2701.
   PubMed Web of Science ®Google Scholar
• Castellon SA, Ganz PA, Bower JE, Petersen L, Abraham L, Greendale GA. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsy 2004;26:955–969.
   PubMed Web of Science ®Google Scholar
• Phillips KA, Bernhard J. Adjuvant breast cancer treatment and cognitive function: current knowledge and research directions. J Natl Cancer I 2003;95:190–197.
   PubMed Web of Science ®Google Scholar
• Poppelreuter RC, Mannes AJ, Clark US, Bennett GJ. Cognitive dysfunction and subjective complaints of cancer patients: a cross-sectional study in a cancer rehabilitation centre. Eur J Cancer 2004;40:43–49.
   PubMed Web of Science ®Google Scholar
• Schagen SB, van Dam FS, Muller MJ, Boogerd W, Lindeboom J, Bruning PF. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 1999;85: 640–650.
   PubMed Web of Science ®Google Scholar
• Mehnert A, Scherwath A, Schirmer L, Schleimer B, Petersen C, Schulz-Kindermann F, Zander AR, Koch U. The association between neuropsychological impairment, self-perceived cognitive deficits, fatigue and health related quality of life in breast cancer survivors following standard adjuvant versus high-dose chemotherapy. Patient Educ Couns 2007;66:108–118.
   PubMed Web of Science ®Google Scholar
• Vardy J, Wefel JS, Ahles T, Tannock IF, Schagen SB. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol 2008;19:623–629.
   PubMed Web of Science ®Google Scholar
• Saykin AJ, Ahles TA, McDonald BC. Mechanisms of chemotherapy-induced cognitive disorders: neuropsychological, pathophysiological, and neuroimaging perspectives. Semin Clin Neuropsy 2003; 8(4):201–216.
   PubMedGoogle Scholar
• Stemmer SM, Stears JC, Burton BS, Jones RB, Simon JH. White matter changes in patients with breast cancer treated with high-dose chemotherapy and autologous bone marrow support. AJNR Am J Neuroradiol 1994;15:1267–1273.
   PubMed Web of Science ®Google Scholar
• Inagaki M, Yoshikawa E, Matsuoka Y, Sugawara Y, Nakano T, Akechi T, Wada N, Imoto S, Murakami K, Uchitomi Y. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer 2007;109:146–156.
   PubMed Web of Science ®Google Scholar
• Saykin AJ, McDonald BC, Ahles TA. Alterations in brain activation during working memory in patients with breast cancer: relation to treatment modality, cancer status and task performance. In 13th Annual Meeting of the Organization for Human Brain Mapping. Neuroimage: Chicago, IL, 2007; pp 36 (Suppl 86).
   Google Scholar
• Ferguson RJ, McDonald BC, Saykin AJ, Ahles TA. Brain structure and function difference in monozygotic twins: possible effects of breast cancer chemotherapy. J Clin Oncol 2007;25:3866–3870.
   PubMed Web of Science ®Google Scholar
• Silverman DH, Dy CJ, Castellon SA, Lai J, Pio BS, Abraham L, Waddell K, Petersen L, Phelps ME, Ganz PA. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5–10 years after chemotherapy. Breast Cancer Res Tr 2007;103:303–311.
   PubMed Web of Science ®Google Scholar
• Bender CM, Sereika SM, Berga SL, Vogel VG, Brufsky AM, Paraska KK, Ryan CM. Cognitive impairment associated with adjuvant therapy in breast cancer. Psycho-Oncology 2006;15:422–430.
   PubMed Web of Science ®Google Scholar
• Ahles T, Saykin A, McDonald B, Furstenberg C, Cole B, Hanscom B, Mulrooney T, Schwartz G, Kaufman P. Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Tr 2008;110:143–152.
   PubMed Web of Science ®Google Scholar
• Hermelink K, Untch M, Lux MP, Kreienberg R, Beck T, Bauerfeind I, Munzel K. Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer 2007;109: 1905–1913.
   PubMed Web of Science ®Google Scholar
• Jansen CE, Miaskowski C, Dodd M, Dowling G, Kramer J. A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer 2005;104:2222–2233.
   PubMed Web of Science ®Google Scholar
• Schagen SB, Muller MJ, Boogerd W, Rosenbrand RM, van Rhijn D, Rodenhuis S, van Dam FSAM. Late Effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol 2002;13:1387–1397.
   PubMed Web of Science ®Google Scholar
• Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 2005;104:788–793.
   PubMed Web of Science ®Google Scholar
• Ahles TA, Silberfarb PM, Herndon J, Maurer LH, Kornblith AB, Aisner J, Perry MC, Eaton WL, Zacharski LL, Green MR, Holland JC. Psychological and neuropsychological functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin, a study for Cancer and Leukemia Group B. J Clin Oncol 1998;16:1954–1960.
   PubMed Web of Science ®Google Scholar
• Wise PM. Estrogen therapy: Does it help or hurt the adult and the aging brain? Insights derived from animal models. Neuroscience 2006;138:831–835.
   PubMed Web of Science ®Google Scholar
• Turgeon JL, Carr MC, Maki PM, Mendelsohn ME, Wise PM. Complex actions of sex steroids in adipose tissue, the cardiovascular system, and brain: insights from basic science and clinical studies. Endocr Rev 2006;27:575–605.
   PubMed Web of Science ®Google Scholar
• Bender CM, Paraska KK, Sereika SM, Ryan CM, Berga SL. Cognitive function and reproductive hormones in adjuvant therapy for breast cancer: a critical review. J Pain Symptom Manag 2001;21:407–424.
   PubMed Web of Science ®Google Scholar
• Espeland MA, Rapp SR, Shumaker SA, Brunner R, Manson JE, Sherwin BB, Hsia J, Margolis KL, Hogan PE, Wallace R, Dailey M, Freeman R, Hays J, for the Women's Health Initiative Memory, S. Conjugated equine estrogens and global cognitive function in postmenopausal women: women's health initiative memory study. JAMA 2004;291:2959–2968.
   PubMed Web of Science ®Google Scholar
• Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, Gass MLS, Stefanick ML, Lane DS, Hays J, Johnson KC, Coker LH, Dailey M, Bowen D. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the women's health initiative memory study: a randomized controlled trial. JAMA 2003;289:2663–2672.
   PubMed Web of Science ®Google Scholar
• Chen D, Chun FU, Shi B, Xu YM. Tamoxifen and toremifene cause impairment of learning and memory function in mice. Pharmacol Biochem Behav 2002;71:277–284.
   PubMedGoogle Scholar
• Paganini-Hill A, Clark LJ. Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Tr 2000;64:165–176.
   PubMed Web of Science ®Google Scholar
• Bender CMP, Sereika SMP, Brufsky AMMDP, Ryan CMP, Vogel VGMDM. HS, Rastogi PMD, Cohen SMP, Casillo FEBSN, Berga SLMD. Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. Menopause 2007;15:995–998.
   Google Scholar
• Schilder CM, Seynaeve C, Beex LV, Boogerd W, Linn SC, Gundy CM, Huizenga HM, Nortier JW, van de Velde CJ, van Dam FS, Schagen SB. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol 2010;28:1294–1300.
   PubMed Web of Science ®Google Scholar
• Phillips K-A, Ribi K, Sun Z, Stephens A, Thompson A, Harvey V, Thürlimann B, Cardoso F, Pagani O, Coates AS, Goldhirsch A, Price KN, Gelber RD, Bernhard J. Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1–98 randomized trial. Breast 2010;19(5):388–395.
   PubMed Web of Science ®Google Scholar
• Ginos JZ, Cooper AJ, Dhawan V, Lai JC, Strother SC, Alcock N, Rottenberg DA. [13N]cisplatin PET to assess pharmacokinetics of intra-arterial versus intravenous chemotherapy for malignant brain tumors. J Nucl Med 1987;28:1844–1852.
   PubMed Web of Science ®Google Scholar
• Dietrich J, Han R, Yang Y, Mayer-Proschel M, Noble M. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol 2006;5:22.
   PubMedGoogle Scholar
• Olivi A, Gilbert M, Duncan KL, Corden B, Lenartz D, Brem H. Direct delivery of platinum-based antineoplastics to the central nervous system: a toxicity and ultrastructural study. Cancer Chemother. Pharmacol. 1993;31:449–454.
   PubMed Web of Science ®Google Scholar
• El-Shazly MO, Afify MMH, El-Dieb MK. Histopathological study into side-effect toxicity of some drugs used in treatment of cancer. Arch. Exp. Vet. Med. 1989;43:319–326.
   PubMedGoogle Scholar
• Clark AW, Parhad IM, Griffin JW, Price DL. Neurotoxicity of cis-platinum: pathology of the central and peripheral nervous systems. Neurology 1980;30:429.
   Web of Science ®Google Scholar
• Troy L, McFarland K, Littman-Power S, Kelly BJ, Walpole ET, Wyld D. Cisplatin-based therapy: a neurological and neuropsychological review. Psycho-Oncology 2000;9:29–39.
   PubMed Web of Science ®Google Scholar
• von Zglinicki T, Martin-Ruiz CM. Telomeres as biomarkers for ageing and age-related diseases. Curr Mol Med 2005;5: 197–203.
   PubMed Web of Science ®Google Scholar
• Maccormick RE. Possible acceleration of aging by adjuvant chemotherapy: a cause of early onset frailty? Med Hypotheses 2006;67:212–215.
   PubMed Web of Science ®Google Scholar
• Vasa-Nicotera M, Brouilette S, Mangino M, Thompson JR, Braund P, Clemitson J, Mason A, Bodycote CL, Raleigh SM, Louis E, Samani NJ. Mapping of a major locus that determines telomere length in humans. Am. J. Hum. Genet. 2005;76:147–151.
   PubMed Web of Science ®Google Scholar
• Schroder CP, Wisman GB, de Jong S, van der Graaf WT, Ruiters MH, Mulder NH, de Leij LF, van der Zee AG, de Vries EG. Telomere length in breast cancer patients before and after chemotherapy with or without stem cell transplantation. Brit J Cancer 2001;84:1348–1353.
   PubMed Web of Science ®Google Scholar
• Zhang RG, Zhang RP. Effects of cisplatinum on telomerase activity and telomere length in BEL-7404 human hepatoma cells. Cell Res 2002;12:56–62.
   Google Scholar
• Fishel ML, Vasko MR, Kelley MR. DNA repair in neurons: so if they don't divide what's to repair? Mutat. Res. 2007;614:24–36.
   PubMed Web of Science ®Google Scholar
• Flanary BE, Streit WJ. Progressive telomere shortening occurs in cultured rat microglia, but not astrocytes. Glia 2004;45:75–88.
   PubMed Web of Science ®Google Scholar
• Yaffe K, Lindquist K, Kluse M, Cawthon R, Harris T, Hsueh W-C, Simonsick EM, Kuller L, Li R, Ayonayon HN, Rubin SM, Cummings SR. Telomere length and cognitive function in community-dwelling elders: findings from the health ABC study. Neurobiol Aging 2011;32(11):2055–2060.
   PubMed Web of Science ®Google Scholar
• Valdes AM, Deary IJ, Gardner J, Kimura M, Lu X, Spector TD, Aviv A, Cherkas LF. Leukocyte telomere length is associated with cognitive performance in healthy women. Neurobiol Aging 2010;31:986–992.
   PubMed Web of Science ®Google Scholar
• Martin-Ruiz C, Dickinson HO, Keys B, Rowan E, Kenny RA, Von Zglinicki T. Telomere length predicts poststroke mortality, dementia, and cognitive decline. Ann Neurol 2006;60:174–180.
   PubMed Web of Science ®Google Scholar
• Caldecott KW. DNA single-strand breaks and neurodegeneration. DNA Repair 2004;3:875–882.
   PubMed Web of Science ®Google Scholar
• Abner CW, McKinnon PJ. The DNA double-strand break response in the nervous system. DNA Repair 2004;3:1141–1147.
   PubMed Web of Science ®Google Scholar
• Mariani EC, PM, Cherubini A, Mecocci P. Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2005;827:65–75.
   PubMed Web of Science ®Google Scholar
• Keller JN, Schmitt FA, Scheff SW, Ding Q, Chen Q, Butterfield DA, Markesbery WR. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 2005;64:1152–1156.
   PubMed Web of Science ®Google Scholar
• Blasiak J, Arabski M, Krupa R, Wozniak K, Rykala J, Kolacinska A, Morawiec Z, Drzewoski J, Zadrozny M. Basal, oxidative and alkylative DNA damage, DNA repair efficacy and mutagen sensitivity in breast cancer. Mutat Res 2004;554:139–148.
   PubMed Web of Science ®Google Scholar
• Nadin SB, Vargas-Roig LM, Drago G, Ibarra J, Ciocca DR. DNA damage and repair in peripheral blood lymphocytes from healthy individuals and cancer patients: a pilot study on the implications in response to chemotherapy. Cancer Lett 2006;239:84–87.
   PubMed Web of Science ®Google Scholar
• Kaya E, Keskin L, Aydogdu I, Kuku I, Bayraktar N, Erkut MA. Oxidant/antioxidant parameters and their relationship with chemotherapy in Hodgkin's lymphoma. J Int Med Res 2005;33:687–692.
   PubMed Web of Science ®Google Scholar
• Kennedy DD, Ladas EJ, Rheingold SR, Blumberg J, Kelly KM. Antioxidant status decreases in children with acute lymphoblastic leukemia during the first six months of chemotherapy. Pediat Blood Cancer 2005;44:378–385.
   PubMed Web of Science ®Google Scholar
• Caron JE, Krull KR, Hockenberry M, Jain N, Kaemingk K, Moore IM. Oxidative stress and executive function in children receiving chemotherapy for acute lymphoblastic leukemia. Pediat Blood Cancer 2009;53:551–556.
   PubMed Web of Science ®Google Scholar
• Miketova P, Kaemingk K, Hockenberry M, Pasvogel A, Hutter J, Krull K, Moore IM. Oxidative changes in cerebral spinal fluid phosphatidylcholine during treatment for acute lymphoblastic leukemia. Biol Res Nurs 2005;6:187–195.
   PubMedGoogle Scholar
• Babiak RM, Campello AP, Carnieri EG, Oliveira MB. Methotrexate: pentose cycle and oxidative stress. Cell Biochem Funct 1998;16:283–293.
   PubMed Web of Science ®Google Scholar
• Girotti AW. Lipid hydroperoxide generation, turnover, and effector action in biological systems. J Lipid Res 1998;39:1529–1542.
   PubMed Web of Science ®Google Scholar
• Farooqui AA, Horrocks LA. Lipid peroxides in the free radical pathophysiology of brain disease. Cell Mol Neurobiol 1998;18:599–608.
   PubMed Web of Science ®Google Scholar
• Moore IM, Miketova P, Hockenberry M. Methotrexate-induced alterations in beta-oxidation correlate with cognitive abilities in children with acute lymphoblastic leukemia. Biol Res Nurs 2008;9:311–319.
   PubMed Web of Science ®Google Scholar
• Joshi G, Sultana R, Tangpong J, Cole MP, St. Clair DK, Vore M, Estus S, Butterfield DA. Free radical mediated oxidative stress and toxic side effects in brain induced by the anti cancer drug adriamycin: insight into chemobrain. Free Radical Res 2005;39:1147–1154.
   PubMed Web of Science ®Google Scholar
• Joshi G, Hardas S, Sultana R, St. Clair DK, Vore M, Butterfield DA. Glutathione elevation by gamma-glutamyl cysteine ethyl ester as a potential therapeutic strategy for preventing oxidative stress in brain mediated by in vivo administration of adriamycin: implication for chemobrain. J Neurosci Res 2007;85:497–503.
   PubMed Web of Science ®Google Scholar
• Tarumi W, Suzuki N, Takahashi N, Kobayashi Y, Kiguchi K, Sato K, Ishizuka B. Ovarian toxicity of paclitaxel and effect on fertility in the rat. J Obstet Gynaecol Res 2009;35:414–420.
   PubMed Web of Science ®Google Scholar
• Henderson VW, Paganini-Hill A, Emanuel CK, Dunn ME, Buckwalter JG. Estrogen replacement therapy in older women: comparisons between Alzheimer's disease cases and nondemented control subjects. Arch Neurol 1994;51:896–900.
   PubMed Web of Science ®Google Scholar
• Robinson D, Friedman L, Marcus R, Tinklenberg J, Yesavage J. Estrogen replacement therapy and memory in older women. J Am Geriatr Soc 1994;42:919–922.
   PubMed Web of Science ®Google Scholar
• Sherwin BB, Gelfand MM. Sex steroids and affect in the surgical menopause: a double-blind, cross-over study. Psychoneuroendrocrinology 1985;10:325–335.
   PubMed Web of Science ®Google Scholar
• Sherwin BB. Hormones, mood, and cognitive functioning in post-menopausal women. Obstet Gynecol 1996;87(2 Suppl):20S–26S.
   PubMed Web of Science ®Google Scholar
• Kritz-Silverstein D, Barrett-Connor E. Hysterectomy, oophorectomy, and cognitive function in older women. J Am Geriatr Soc 2002;50:55–61.
   PubMed Web of Science ®Google Scholar
• Hao J, Rapp PR, Leffler AE, Leffler SR, Janssen WGM, Lou W, McKay H, Roberts JA, Wearne SL, Hof PR, Morrison JH. Estrogen alters spine number and morphology in prefontal cortex of aged female rhesus monkeys. J Neurosci 2006;26:2571–2578.
   PubMed Web of Science ®Google Scholar
• Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer's disease. Amer J Epid 1994;140:256–261.
   PubMed Web of Science ®Google Scholar
• Sherwin BB. Estrogen and cognitive function in women. Proc Soc Exper Biol Med 1998;217:17–22.
   PubMed Web of Science ®Google Scholar
• Luine VN. Estradiol increases choline acetyltransferase activity in specific basal forebrain nuclei and projection areas of female rats. Exper Neurol 1985;89:484–490.
   PubMed Web of Science ®Google Scholar
• Unfer TC, Conterato GM, da Silva JC, Duarte MM, Emanuelli T. Influence of hormone replacement therapy on blood antioxidant enzymes in menopausal women. Clinica Chimica Acta 2006;369:73–77.
   PubMed Web of Science ®Google Scholar
• Strehlow K, Rotter S, Wassmann S, Adam O, Grohé C, Laufs K, Böhm M, Nickenig G. Modulation of antioxidant enzyme expression and function by estrogen. Circ Res 2003;93:170–177.
   PubMed Web of Science ®Google Scholar
• Lee DC, Im JA, Kim JH, Lee HR, Shim JY. Effect of long-term hormone therapy on telomere length in postmenopausal women. Yonsei Med J 2005;46:471–479.
   PubMed Web of Science ®Google Scholar
• Benetos A, Okuda K, Lajemi M, Kimura M, Thomas F, Skurnick J, Labat C, Bean K, Aviv A. Telomere length as an indicator of biological aging: the gender effect and relation with pulse pressure and pulse wave velocity. Hypertension 2001;37:381–385.
   PubMed Web of Science ®Google Scholar
• Rahimian R, Chan L, Goel A, Poburko D, Van Breemen C. Estrogen modulation of endothelium-derived relaxing factors by human endothelial cells. Biochem Biophys Res Commun 2004;322:373–379.
   PubMed Web of Science ®Google Scholar
• Vasa M, Breitschopf K, Zeiher AM, Dimmeler S. Nitric oxide activates telomere and delays endothelial cell sensecence. Circ Res 2000;87:540–542.
   PubMed Web of Science ®Google Scholar
• Wilson CJ, Finch CE, Cohen HJ. Cytokines and cognition- the case for head-to-toe inflammatory paradigm. J Am Geriatr Soc 2002;50:2041–2056.
   PubMed Web of Science ®Google Scholar
• Maier SF, Watkins LR. Immune-to-central nervous system communication and its role in modulating pain and cognition: implications for cancer and cancer treatment. Brain Behav Immun 2003;17:S125–S131.
   PubMed Web of Science ®Google Scholar
• Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A, Pollmacher T. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001;58:445–452.
   PubMed Web of Science ®Google Scholar
• Krabbe KS, Reichenberg A, Yirmiya R, Smed A, Pedersen BK, Bruunsgaard H. Low-dose endotoxemia and human neuropsychological functions. Brain Behav Immun 2005;19:453–460.
   PubMed Web of Science ®Google Scholar
• Tonelli LH, Postolache TT, Sternberg EM. Inflammatory genes and neural activity: involvement of immune genes in synaptic function and behavior. Front Biosci 2005;10:675–680.
   PubMed Web of Science ®Google Scholar
• Pusztai L, Mendoza TR, Reuben JM, Martinez MM, Willey JS, Lara J, Syed A, Fritsche HA, Bruera E, Booser D, Valero V, Arun B, Ibrahim N, Rivera E, Royce M, Cleeland CS, Hortobagyi GN. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 2004;25:94–102.
   PubMed Web of Science ®Google Scholar
• Penson RT, Kronish K, Duan Z, Feller AJ, Stark P, Cook SE, Duska LR, Fuller AF, Goodman AK, Nikrui N, MacNeill KM, Matulonis UA, Preffer FI, Seiden MV. Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNF-alpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer 2001;10:33–41.
   Web of Science ®Google Scholar
• Tsaavaris N, Kosmas C, Vadiaka M, Kanelopoulous P, Boulamatsis D. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Brit J Cancer 2002;87:21–27.
   PubMed Web of Science ®Google Scholar
• Plata-Salaman CR, French-Mullen JM. Interleukin-1 beta depresses calcium currents in CA1 hippocampal neurons at pathophysiological concentrations. Brain Res Bull 1992;29:221–223.
   PubMed Web of Science ®Google Scholar
• Ellison MD, Merchant RE. Appearance of cytokine-associated central nervous system myelin damage coincides temporally with serum tumor necrosis factor induction after recombinant interleukin-2 infusion in rats. J Neuroimmunol 1991;33:245–251.
   PubMed Web of Science ®Google Scholar
• Larson S, Dunn AJ. Behavioral effects of cytokines. Brain Behav Immun 2001;15:371–387.
   PubMed Web of Science ®Google Scholar
• Meyers CA, Valentine AD. Neurological and psychiatric adverse effects of immunological therapy. CNS Drugs 1995;3:56–68.
   Web of Science ®Google Scholar
• Kelley KW, Bluthé R-M, Dantzer R, Zhou J-H, Shen W-H, Johnson RW, Broussard SR. Cytokine-induced sickness behavior. Brain Behav Immun 2003;17:112–118.
   PubMed Web of Science ®Google Scholar
• Cleeland CS, Bennett GJ, Dantzer R, Dougherty PM, Dunn AJ, Meyers CA, Miller AH, Payne R, Reuben JM, Wang XS, Lee B-N. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? Cancer 2003;97:2919–2925.
   PubMed Web of Science ®Google Scholar
• Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P, Boulamatsis D. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer 2002;87:21–27.
   PubMed Web of Science ®Google Scholar
• Meyers CA, Abbruzzese JL. Cognitive functioning in cancer patients: effects of previous treatment. Neurology 1992;42:434–436.
   PubMed Web of Science ®Google Scholar
• Trask PC, Esper P, Riba M, Redman B. Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. J Clin Oncol 2000;18:2316–2326.
   PubMed Web of Science ®Google Scholar
• Scheibel RS, Valentine AD, O'Brien S, Meyers CA. Cognitive dysfunction and depression during treatment with interferon-alpha and chemotherapy. J Neuropsych Clin N 2004;16:185–191.
   PubMed Web of Science ®Google Scholar
• Ahles TA, Saykin AJ, Noll WW, Furstenberg CT, Guerin S, Cole B, Mott LA. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psycho-Oncology 2003;12:612–619.
   PubMed Web of Science ®Google Scholar
• Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. 2000;97:3473–3478.
   Google Scholar
• Jamroziak K, Robak T. Pharmacogenomics of MDR1/ABCB1 Gene: the influence on risk and clinical outcome of haematological malignancies. Hematology 2004;9:91–105.
   PubMedGoogle Scholar
• Muramatsu T, Johnson DR, Finch RA, Johnson LK, Leffert JJ, Lin ZP, Pizzorno G, Sartorelli A. Age-related differences in vincristine toxicity and biodistribution in wild-type and transporter-deficient mice. Oncol Res 2004;14:331–343.
   PubMed Web of Science ®Google Scholar
• Pang PT, Lu B. Regulation of late-phase LTP and long-term memory in normal and aging hippocampus: role of secreted proteins tPA and BDNF. Ageing Res Rev 2004;3:407–430.
   PubMed Web of Science ®Google Scholar
• Savitz J, Solms M, Ramesar R. The molecular genetics of cognition: dopamine, COMT and BDNF. Genes, Brain and Behavior 2006;5:311–328.
   PubMed Web of Science ®Google Scholar
• Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, Zaitsev E, Gold B, Goldman D, Dean M, Lu B, Weinberger DR. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003;112:257–269.
   PubMed Web of Science ®Google Scholar
• Hariri AR, Goldberg TE, Mattay VS, Kolachana BS, Callicott JH, Egan MF. Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J Neurosci 2003;23:6690–6694.
   PubMed Web of Science ®Google Scholar
• Pezawas L, Verchiniski BA, Mattay VS, Callicott JH, Kolachana BS, Straub RE, Egan MF, Meyer-Lindenberg A, Weinberger DR. The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology. J Neurosci 2004;24:10099–10102.
   PubMed Web of Science ®Google Scholar
• Malhotra AK, Kestler LJ, Mazzanti C, Bates JA, Goldberg T, Goldman D. A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition. Am J Psychiatry 2002;159:652–654.
   PubMed Web of Science ®Google Scholar
• Fardell J, Vardy J, Shah J, Johnston I. Cognitive impairments caused by oxaliplatin and 5-fluorouracil chemotherapy are ameliorated by physical activity. Psychopharmacology 2011; in press.
   Google Scholar
• Aluise CD, Miriyala S, Noel T, Sultana R, Jungsuwadee P, Taylor TJ, Cai J, Pierce WM, Vore M, Moscow JA, St Clair DK, Butterfield DA. 2-Mercaptoethane sulfonate prevents doxorubicin-induced plasma protein oxidation and TNF-α release: implications for the reactive oxygen species-mediated mechanisms of chemobrain. Free Radical Bio Med 2011;50:1630–1638.
   PubMed Web of Science ®Google Scholar
• Wefel JS, Vardy J, Ahles T, Schagen SB. International cognition and cancer task force recommendations to harmonise studies of cognitive function in patients with cancer. The Lancet Oncol 2011;12:703–708.
   PubMed Web of Science ®Google Scholar
• de Jong N, Candel MJ, Schouten HC, Abu-Saad HH, Courtens AM. Course of mental fatigue and motivation in breast cancer patients receiving adjuvant chemotherapy. Ann Oncol 2005;16:372–382.
   PubMed Web of Science ®Google Scholar
• Tchen N, Juffs HG, Downie FP, Yi Q-L, Hu H, Chemerynsky I, Clemons M, Crump M, Goss PE, Warr D, Tweedale ME, Tannock IF. Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol 2003;21:4175–4183.
   PubMed Web of Science ®Google Scholar
• Hermelink K, Henschel V, Untch M, Bauerfeind I, Lux MP, Munzel K. Short term effects of treatment induced hormonal changes on cognitive function in breast cancer patients. Cancer 2008;113:2431–2439.
   PubMed Web of Science ®Google Scholar
• Jenkins V, Shilling V, Fallowfield L, Howell A, Hutton S. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psycho-Oncology 2004;13:61–66.
   PubMed Web of Science ®Google Scholar
• Schilder CM, Eggens PC, Seynaeve C, Linn SC, Boogerd W, Gundy CM, Beex LV, Van Dam FS, Schagen SB. Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study. Acta Oncol 2009;48:76–85.
   PubMed Web of Science ®Google Scholar
• Collins B, Mackenzie J, Stewart A, Bielajew C, Verma S. Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study. Psycho-Oncology 2009;18:811–821.
   PubMed Web of Science ®Google Scholar